EAF1/TID1 modulators (Gardant/Avantogen)

N/A

Report date: 2025/03/18 20:00:05

NME

Base Information

Drug NameEAF1/TID1 modulators (Gardant/Avantogen)

Drug Alias NameEAF1/TID1 modulators (Bioaccelerate/AustCancer)EAF1/TID1 modulators (Gardant/AustCancer)calreticulincalreticulin/TID1 modulators (Gardant/AustCancer)calreticulin/TID1 modulators (ardant/Avantogen) +[8]

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia and New Zealand

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGardant Pharmaceuticals

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGardant Pharmaceuticals Acuvax

Active IndicationsN/A

Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A